First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC).Johanna C. Bendell, Johann S. de Bono, Ashley E. Ross et al.|Journal of Clinical Oncology|2020Cited by 20
Soluble CLEC2 Extracellular Domain Improves Glucose and Lipid Homeostasis by Regulating Liver Kupffer Cell PolarizationXinle Wu, Yang Li, Jun Zhang et al.|EBioMedicine|2015Cited by 8